GHAPPcast7 Tammi 2025

Medication Review: What is non-responder imputation and how is it utilized in clinical trials?

Thank you to Johnson & Johnson for your support of this Medication Review Video Module.

Clinical trials play a crucial role in guiding treatment decisions, but the way missing data is handled can significantly impact the results. In this medication review video module, Whitney Steinmetz, NP, from Presbyterian Medical Group in Albuquerque, NM, explains the concept of non-responder imputation (NRI)—a widely used statistical method in clinical trials.

Non-responder imputation is a conservative approach used to address missing data by assuming that participants who drop out or have missing responses did not respond to treatment. This method helps prevent overestimating a therapy’s effectiveness, ensuring that clinical trial results remain reliable. However, it can also underestimate a treatment’s true impact, particularly if patients drop out for reasons unrelated to treatment failure. Understanding how this statistical method influences trial outcomes is essential for healthcare providers, as it directly affects the interpretation of treatment efficacy and patient care decisions.

By reducing bias and offering a straightforward approach to data analysis, non-responder imputation helps maintain the integrity of clinical trial results. However, its conservative nature can sometimes skew findings, making a treatment appear less effective than it actually is. This is why it’s important for clinicians to be aware of how missing data is managed in studies. If non-responder imputation was used, the reported effectiveness of a treatment might be a cautious estimate rather than a complete reflection of its potential benefits.

For more information please visit the GHAPP website or download the GHAPP ACE app.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(155)

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Kesä 4min

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Touko 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Touko 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Touko 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Touko 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Huhti 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Huhti 23min